Date: 2017-05-02
Type of information: Nomination
Compound:
Company: Verastem (US - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 2, 2017, Verastem announced the appointment of Eric K. Rowinsky to its Board of Directors. Dr. Rowinsky brings to Verastem nearly 30 years of experience in the development of cancer treatments, such as cetuximab (Erbitux®) when he was Chief Medical Officer of ImClone Systems, as well as ramucirumab, necitumumab, paclitaxel, docetaxel, topotecan, erlotinib, irinotecan, lapatinib, and cixutumumab, among others. Dr. Rowinsky currently serves on the Board of Directors for several biotechnology and pharmaceutical companies including Biogen.
- Dr. Rowinsky is replacing Dr. Paul Friedman who is transitioning from his role as Director to become a member of Verastem’s Clinical and Scientific Advisory Board (CSAB).
Financial terms:
Latest news:
Is general: Yes
